An Isolated Urodynamic Number: Treating Detrusor Leak-Point Pressure Alone
A young man with spina bifida has a single elevated pressure reading on surveillance urodynamics and no symptoms at all. The disagreement is whether that number alone justifies starting a drug he doesn't otherwise need.
Walt O., a 26-year-old man who finished his HVAC certification two years ago and has been steadily building a client list ever since, was born with a lumbosacral myelomeningocele and transitioned out of pediatric urology care at 19 without much fanfare — he catheterizes four times a day, has never had a febrile urinary tract infection as an adult, and describes his bladder as "the thing that just works in the background," a phrase his transition-clinic nurse has heard from him at three straight annual visits. This year's surveillance urodynamic study, done as it has been every year since childhood, showed a detrusor leak-point pressure of 48 cm H2O — the first time it has crossed 40 in his adult chart, though his renal ultrasound the same week was unremarkable and his creatinine is unchanged from two years ago.
The 40 cm H2O threshold traces back to McGuire, Woodside, and Borden's original work in children with myelodysplasia, where pressures above that level correlated with a real, measurable rise in upper urinary tract deterioration — the finding this entire surveillance practice was built around. Tarcan's later cohort of 193 children, assessed at age three, unsettles it from two directions at once. The seventy who went on to develop upper tract damage and the hundred twenty-three who didn't had statistically indistinguishable leak-point pressures (median 42.5 versus 39.5 cm H2O, p=0.087), and 62% of the children whose pressures sat above 40 had entirely normal upper tracts anyway — but the same analysis found a 20 cm H2O cutoff far more sensitive for damage, which is an argument that 40 is too permissive, not that it is too strict. The adult data are what is genuinely thin, and thinner than the room is treating it: Lane and colleagues followed forty-two adults with congenital neurogenic bladder and leak-point pressures over 40, managed without surgery on close urodynamic and ultrasound follow-up, and no patient advanced a stage of chronic kidney disease across nearly three years. Their median entry pressure was 49 cm H2O. Walt's is 48. He is not, as the discussion keeps half-assuming, a pediatric threshold applied blind to a grown man — he is a near-exact match for the one adult series that exists, and what that series tested is the very plan of watching rather than treating.
Annual transition-clinic urodynamics review
I'd start an antimuscarinic now, not wait for symptoms or imaging changes to appear. And I want to be careful about how the threshold critique gets used in this room, because it doesn't say what people think it says. Tarcan's cohort didn't conclude that 40 was too aggressive — it concluded that 20 predicted upper tract damage more sensitively than 40 did. Read straight, that data says Walt crossed a meaningful line some time before this year, and we're only noticing now because we picked the wrong line to watch. Waiting for hydronephrosis means treating after the protective window has already started closing.
That cuts both ways and you know it.
The same cohort found sixty-two percent of the children above 40 had entirely normal upper tracts, and no significant difference in leak-point pressure at all between those who deteriorated and those who didn't — a three-point gap that didn't clear significance in the population the number was derived from. And Walt isn't in that population: he's an adult, his imaging is normal, his creatinine is stable. Lane's adult series is the closer comparison, and those patients — entry pressures right around his — went nearly three years on close surveillance without a single one advancing a stage of kidney disease. I'd repeat the study in three to six months before committing him to a lifelong medication on the strength of one reading.
There's a version of this that doesn't require resolving whose reading of the threshold is right. An antimuscarinic isn't free — dry mouth, constipation, and for a working adult, a real daily nuisance — against a benefit that's disputed even in the pediatric data it's extrapolated from.
I'd repeat the urodynamic study in three months, as Dr. Iyer suggests, and treat only if the elevated pressure is reproducible rather than a single measurement — that gives us more information before committing Walt to a drug he currently has no symptomatic reason to take, without simply waiting for actual kidney damage the way Dr. Reyes is worried about.
Agreed: repeat urodynamic study and renal ultrasound in three months rather than start antimuscarinic therapy today; treat only if the elevated pressure reproduces.
Not agreed: the urologist would have started treatment today given the surveillance model's original intent, and views the three-month wait as accepting real risk during a window the whole point of surveillance is meant to close — outvoted here, but recorded so a reproducible reading at follow-up is acted on without re-litigating this same argument.